Assessment of anti-migraine potential of a novel α-adrenoceptor agonist S19014: Effects on porcine carotid and regional haemodynamics and human coronary artery

Cephalalgia

Volumn 24, Issue 6, 2004, Pages 425-438

  Kapoor, K ^a   Willems, E W ^a   MaassenVanDenBrink, A ^a   Heiligers, J P C ^a   Cordi, A A ^b   Vayssettes Courchay, C ^b   Verbeuren, T J ^b   Villalon C M ^c   Saxena, P R ^a  

^a ERASMUS UNIVERSITY ROTTERDAM   (Netherlands)

^b IRIS Institut de Recherches Internationales Servier   (France)

^c DEPARTAMENTO DE FÍSICA   (Mexico)

Author keywords

Adrenoceptors; Arteriovenous anastomoses; Cardiac output; Microspheres; Migraine; Prazosin; Rauwolscine; S19014; Vasoconstriction

Indexed keywords

15 HYDROXY 11ALPHA,9ALPHA EPOXYMETHANOPROSTA 5,13 DIENOIC ACID; ALPHA ADRENERGIC RECEPTOR; ALPHA ADRENERGIC RECEPTOR STIMULATING AGENT; FUMARIC ACID DERIVATIVE; PRAZOSIN; RAUWOLSCINE; S 190014; SPIRO[(1,3 DIAZACYCLOPENT 1 ENE) 5:2' (4',5' DIMETHYLINDANE)]FUMARATE; SUMATRIPTAN; UNCLASSIFIED DRUG;

ANIMAL TISSUE; ARTERIOVENOUS FISTULA; ARTICLE; CAPILLARY FLOW; CAROTID ARTERY; CAROTID ARTERY FLOW; CONDUCTANCE; CONTROLLED STUDY; CORONARY ARTERY; DOSE RESPONSE; DRUG DOSE REGIMEN; DRUG EFFECT; DRUG POTENCY; DRUG POTENTIATION; DRUG SCREENING; HEMODYNAMIC MONITORING; HUMAN; HUMAN TISSUE; ISOLATION PROCEDURE; NONHUMAN; SWINE;

ADRENERGIC ALPHA-AGONISTS; ADULT; ANIMALS; CARDIAC OUTPUT; CAROTID ARTERY, COMMON; CORONARY VESSELS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; INDANS; MALE; MIDDLE AGED; MIGRAINE DISORDERS; RECEPTORS, ADRENERGIC, ALPHA; REGIONAL BLOOD FLOW; SPIRO COMPOUNDS; SWINE; VASOCONSTRICTION;

EID: 2942517658     PISSN: 03331024     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1468-2982.2004.00684.x     Document Type: Article

References (52)

1. Heyck H. Pathogenesis of migraine. Res Clin Stud Headache 1969; 2:1-28.
2. Saxena PR. Cranial arteriovenous shunting, an in vivo animal model for migraine. In: Olesen J, Moskowitz MA, eds. Experimental headache models. Philadelphia, USA: Lippincott-Raven Publishers, 1995, 189-98.
3. De Vries P, Villalón CM, Saxena PR. Pharmacological aspects of experimental headache models in relation to acute antimigraine therapy. Eur J Pharmacol 1999; 375:61-74.
4. Villalón CM, Centurión D, Valdivia LF, De Vries P, Saxena PR. An introduction to migraine: from ancient treatment to functional pharmacology and antimigraine therapy. Proc West Pharmacol Soc 2002; 45:199-210.
5. 1-like receptors. Br J Pharmacol 1991; 104:183-9.
6. 1B/1D and novel receptors. Br J Pharmacol 1998; 123:1561-70.
7. 2-adrenoceptors. Br J Pharmacol 1999; 126:385-94.
8. 1-adrenoceptor subtypes involved in adrenergic contractions of dog blood vessels. Br J Pharmacol 1994; 112:1167-73.
9. Kawai Y, Kobayashi S, Ohhashi T. Existence of two types of postjunctional α-adrenoceptors in the isolated canine internal carotid artery. Can J Physiol Pharmacol 1988; 66:655-9.
10. 1- adrenoceptor subtypes involved in noradrenaline contraction of the rabbit thoracic aorta. Br J Pharmacol 1990; 101:662-6.
11. 1- adrenoceptors involved in noradrenaline-induced contractions of rat thoracic aorta and dog carotid artery. Jpn J Pharmacol 1991; 57:535-44.
12. Ohgushi M, Yasue H, Kugiyama K, Murohara T, Sakaino N. Contraction and endothelium dependent relaxation via α-adrenoceptors are variable in various pig arteries. Cardiovasc Res 1993; 27:779-84.
13. 2-adrenoceptors mediate vasoconstriction of carotid arteriovenous anastomoses in anaesthetized pigs. Br J Pharmacol 1999; 127:1263-71.
14. Den Boer MO, Van Woerkens LJ, Somers JA, Duncker DJ, Lachmann B, Saxena PR et al. On the preservation and regulation of vascular tone in arteriovenous anastomoses during anesthesia. J Appl Physiol 1993; 75:782-9.
15. Willems EW, Valdivia LF, Villalón CM, Saxena PR. Possible role of α-adrenoceptor subtypes in acute migraine therapy. Cephalalgia 2003; 23:245-57.
16. Cordi AA, Lacoste JM, Descombes JJ, Vayssettes-Courchay C, Vanhoutte PM, Laubie M et al. Design, synthesis, and structure-activity relationships of a new series of alpha-adrenergic agonists: spiro[(1,3-diazacyclopent-1-ene) -5,2′-(1′,2′,3′,4′- tetrahydronaphthalene)]. J Med Chem 1995; 38:4056-69.
17. Vayssettes-Courchay C, Lacoste J-M, Cordi AA, Laubi M, Verbeuren TJ. In vivo cardiovascular effects of the α-adrenoceptors agonist S18149 in the anaesthetised dog. Br J Pharmacol 1996; 117:225P.
18. Descombes J-J, Menant Y, Barou A, Cordi A, Verbeuren TJ. S19014 is a partial agonist at α-adrenoceptors that selectively contracts the veins. Pharmacol Toxicol 1998; 83 (Suppl. 1):92.
19. 1-like receptors in the reduction of porcine cranial arteriovenous anastomotic shunting by sumatriptan. Br J Pharmacol 1991; 102:323-30.
20. Spierings EL, Saxena PR. Effect of isometheptene on the distribution and shunting of 15-μM microspheres throughout the cephalic circulation of the cat. Headache 1980; 20:103-6.
21. Willems EW, Valdivia LF, Saxena PR, Villalón CM. Pharmacological profile of the mechanisms involved in the external carotid vascular effects of the antimigraine agent isometheptene in anaesthetised dogs. Naunyn Schmiedebergs Arch Pharmacol 2001; 364:27-32.
22. MaassenVanDenBrink A, Reekers M, Bax WA, Ferrari MD, Saxena PR. Coronary side-effect potential of current and prospective antimigraine drugs. Circulation 1998; 98:25-30.
23. MaassenVanDenBrink A, Van den Broek RWM, De Vries R, Bogers AJJC, Avezaat CJJ, Saxena PR. Craniovascular selectivity of eletriptan and sumatriptan in human isolated blood vessels. Neurology 2000; 55:1524-30.
24. Saxena PR, Schamhardt HC, Forsyth RP, Hoeve J. Computer programs for the radioactive microsphere technique. Determination of regional blood flows and other haemodynamic variables in different experimental circumstances. Comput Programs Biomed 1980; 12:63-84.
25. Saxena PR, Verdouw PD. Redistribution by 5-hydroxytryptamine of carotid arterial blood at the expense of arteriovenous anastomotic blood flow. J Physiol (Lond) 1982; 332:501-20.
26. Baile EM, Nelems JM, Schlzer M, Pare PD. Measurement of regional bronchial arterial blood flow and bronchovascular resistance in dogs. J Appl Physiol 1982; 53:1044-9.
27. Steel RGD, Torrie JH. Principles and procedures of statistics. A biomedical approach, 2nd edn. Tokyo, Japan: McGraw-Hill Kogakusha Ltd, 1980.
28. MaassenVanDenBrink A, Bax WA, Ferrari MD, Zijlstra FJ, Bos E, Saxena PR. Augmented contraction of the human isolated coronary artery by sumatriptan; a possible role for endogenous thromboxane. Br J Pharmacol 1996; 119:855-62.
29. Brodde OE, Michel MC. Adrenergic and muscarinic receptors in the human heart. Pharmacol Rev 1999; 51:651-90.
30. 2-adrenoceptors. Prog Drug Res 1996; 47:81-130.
31. 1-adrenoceptors: consensus update. Pharmacol Rev 1995; 47:267-70.
32. 1-adrenoceptors. Eur Urol 1999; 36:2-6.
33. 2-adrenoceptors. Eur J Pharmacol 1998; 361:1-15.
34. 2-adrenoceptor subtypes mediating vasoconstriction in the canine external carotid circulation. Br J Pharmacol 2001; 132:1292-8.
35. Willems EW, Valdivia LF, Ramírez-San Juan E, Saxena PR, Villalón CM. Pharmacological identification of the major subtypes of adrenoceptors involved in the canine external carotid vasoconstrictor effects of adrenaline and noradrenaline. Life Sci 2001; 69:143-53.
36. Saxena PR, MaassenVanDenBrink A, Heiligers JP, Scalbert E, Lemaitre BG. Effects of S20749, a close analogue of sumatriptan, on porcine carotid haemodynamics and human isolated coronary artery. Pharmacol Toxicol 1996; 79:199-204.
37. 1B/1D receptor ligand, in experimental models predictive of antimigraine activity and coronary side-effect potential. Eur J Pharmacol 1998; 351:329-39.
38. Den Boer MO, Somers JA, Saxena PR. Comparative effects of the antimigraine drugs sumatriptan and ergotamine on the distribution of cardiac output in anaesthetized pigs. Cephalalgia 1992; 12:206-13.
39. Tfelt-Hansen P, Saxena PR, Dahlof C, Pascual J, Lainez M, Henry P et al. Ergotamine in the acute treatment of migraine: a review and European consensus. Brain 2000; 123:9-18.
40. Wu CH, Lindsey DC, Traber DL, Cross CE, Herndon DN, Kramer GC. Measurement of bronchial blood flow with radioactive microspheres in awake sheep. J Appl Physiol 1988; 65:1131-9.
41. Kenakin T. Pharmacologic analysis of drug-receptor interaction, 2nd edn. New York: Raven Press, 1993, 483.
42. MaassenVanDenBrink A, Bax WA, Ramrattan NN, Ferrari MD, Saxena PR. Human isolated coronary artery contraction to sumatriptan; a post hoc analysis. Cephalalgia 1999; 19:651-4.
43. 2-adrenoceptor activation. Circ Res 1999; 85:965-9.
44. Olesen IJ, Edvinsson L. Human cranial arteries as an in vitro model of migraine. In: Olesen, J, Moskowitz, MA, eds. Experimental headache models. Philadelphia: Lippincott-Raven Publishers 1995, 143-51.
45. 1F-receptor activation. Br J Clin Pharmacol 1999; 47:75-32.
46. Tfelt-Hansen P, De Vries P, Saxena PR. Triptans in migraine: a comparative review of pharmacology, pharmacokinetics and efficacy. Drugs 2000; 60:1259-87.
47. Baumgart D, Haude M, Gorge G, Liu F, Ge J, Grosse-Eggebrecht C et al. Augmented α-adrenergic constriction of atherosclerotic human coronary arteries. Circulation 1999; 99:2090-7.
48. Heusch G, Baumgart D, Camici P, Chilian W, Gregorini L, Hess O et al. α-Adrenergic coronary vasoconstriction and myocardial ischemia in humans. Circulation 2000; 101:689-94.
49. De Boer AC, Turpie AGC, Butt RW, Johnston RV, Genton E. Platelet release and thromboxane synthesis in symptomatic coronary artery disease. Circulation 1982; 66:327-33.
50. Rubanyi GM, Frye RL, Holmes DR, Vanhoutte PM. Vasoconstrictor activity of coronary sinus plasma from patients with coronary artery disease. J Am Coll Cardiol 1987; 9:1243-9.
51. 2 levels in patients with classic and variant angina pectoris. Circulation 1981; 64:107-15.
52. 2- adrenoceptor-mediated vasoconstriction by the thromboxane-mimetic U46619 in the porcine isolated ear artery: role of the ERK-MAP kinase signal transduction cascade. Br J Pharmacol 2003; 139:156-62.